文献速递MDS 与骨髓增殖性肿瘤

原发性骨髓纤维化生存20年以上患者的表型特征

20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients.
PubMed 文献 · Am J Hematol · 2018-12-05

该研究纳入1282例原发性骨髓纤维化患者,其中26例(2%)生存至少20年,626例(49%)在诊断后5年内死亡。多因素分析显示,年龄≤70岁、女性、血红蛋白达标、白细胞≤25×10⁹/L、血小板≥100×10⁹/L、外周血原始细胞<2%及无体质性症状与生存超过20年相关;而高危分子突变、不良核型、CALR 1型/类突变缺失等与5年死亡率独立相关。

要点

  • 年龄≤70岁、女性、血红蛋白≥10 g/dL(女)或≥11 g/dL(男)等7项临床指标与生存超过20年相关。
  • 高危分子突变、不良核型、CALR 1型/类突变缺失等与5年内死亡独立相关。
  • 遗传风险因素与早期死亡相关,而长期生存可由易获取的临床变量预测。

核心结论

  • 原发性骨髓纤维化的遗传风险因素与早期死亡相关,而生存超过20年可由年龄、性别、血细胞计数和症状等易获取的临床变量预测。

研究设计与样本

  • 研究纳入1282例原发性骨髓纤维化患者(中位年龄65岁,范围19-92;男性63%),其中26例(2%)生存至少20年(中位年龄51岁,范围28-71;男性38%),626例(49%)在诊断后5年内死亡(中位年龄68岁,范围27-92;男性66%)。

主要发现

  • 多因素逻辑回归分析确定7个与生存超过20年相关的变量:年龄≤70岁(P=0.002);女性(P=0.03);女性血红蛋白≥10 g/dL和男性≥11 g/dL(P=0.03);白细胞计数≤25×10⁹/L(P=0.009);血小板计数≥100×10⁹/L(P=0.002);外周血原始细胞<2%(P=0.03);无体质性症状(P=0.04)。
  • 5年死亡率独立预测因素包括:高分子的风险突变(P<0.001);不良或极高风险核型(P<0.001);CALR 1型/类突变缺失(P<0.001);年龄>70岁(P<0.001);体质性症状(P<0.001);女性血红蛋白<10 g/dL和男性<11 g/dL(P<0.001);白细胞计数>25×10⁹/L(P=0.004);外周血原始细胞≥2%(P=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the last decade, several prognostic models for primary myelofibrosis (PMF) have been introduced and shown to be effective in predicting overall survival. The main objective for this study was to identify clinical and genetic markers of very long (20+ years) survival in PMF. A total of 1282 patients with PMF were considered (median age 65 years, range 19-92; 63% males); 26 (2%) patients (median age 51 years, range 28-71; 38% males) survived their disease for at least 20 years (long-lived patients) and 626 (49%) patients (median age 68 years, range 27-92; 66% males) died within 5 years of their diagnosis (short-lived patients). Multivariable logistic regression analysis identified 7 variables that were associated with survival beyond 20 years: age ≤ 70 years (P = .002); female sex (P = .03); hemoglobin level ≥ 10 g/dL for women and ≥ 11 g/dL for men (P = .03), leukocyte count ≤25 × 109 /L (P = .009), platelet count ≥100 × 109 /L (P = .002), circulating blasts <2% (P = .03) and absence of constitutional symptoms (P = .04). Five-year mortality was independently predicted by high-molecular risk mutations (P < .001); unfavorable or very high risk karyotype (P < .001); absence of type 1/like CALR mutation (P < .001); age > 70 years (P < .001); constitutional symptoms (P < .001); hemoglobin level < 10 g/dL for women and < 11 g/dL for men (P < .001); leukocyte count >25 × 109 /L (P = .004); and circulating blasts ≥2% (P = .001). This study suggests that genetic risk factors in PMF are associated with early mortality while survival beyond 20 years could be predicted by easily accessible clinical variables, including age, sex, blood counts, and symptoms.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Penna D, Lasho TL, Finke CM, et al. 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. Am J Hematol. 2018. PMID: 30516867. doi:10.1002/ajh.25351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。